Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. The company markets and sells its products through in-house sales agents and distributors. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.

Marker Gene Technologies sells itself. The company offers drug researchers a variety of marker genes for monitoring gene expression, intracellular targeting, and other purposes. The company's marker genes are used in research for agricultural biotechnology, cell culturing, and bacteriology. Additional products include reagents, enzyme substrates and kits, and other molecular biology products. Marker Gene Technologies also maintains four fully equipped laboratories from which it provides contract research services for biotechnology and pharmaceutical clients. The firm markets its products through a number of distributors in the US and abroad, in Europe, Asia, and the Middle East.

Semafore Pharmaceuticals is signaling its arrival on the oncology drug making scene. The development-stage drug discovery company is targeting the PI3K cell signaling pathways to create anti-cancer drugs. Its PI3K Inhibitors induce the death of cancerous cells in the treatment of tumors and could potentially treat brain, lung, and hematological cancers. Once administered, its lead candidate SF1126 attacks proteins expressed in tumors, but ignores healthy cells. Semafore has brought on a consulting firm to help shepherd SF1126 through its next stage of development.

Shanghai Pharmaceutical Group, or SPGC, knows that Big Pharma is big business. One of China's largest pharmaceutical companies, SPGC makes over-the-counter (OTC) medicines, prescription drugs, active pharmaceutical ingredients (APIs), biopharmaceuticals, and traditional Chinese medicine. The vertically-integrated company distributes its wares and owns more than 1,000 retail locations. SPGC sells drugs in 30 countries from five foreign offices. Its R&D facility, Central Research Institute, operates 10 centers across China. In 1996 many small producers, including Sine, Dragon & Tiger, and Pioneer, merged to form SPGC.

Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts. Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; and M118, an anticoagulant. The company also involves in developing generic or biosimilar glycoprotein products. Momenta Pharmaceuticals has collaborations with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002.

Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina. Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It offers droxidopa, an orally active synthetic precursor of norepinephrine, which is in two double-blind pivotal Phase III trials for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinson's disease, and intradialytic hypotension; for the treatment of intradialytic hypotension for which it has completed a double-blind placebo controlled Phase II study; and for the treatment of fibromyalgia that is in a Phase II trial.Chelsea Therapeutics company also offers a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a Phase II head-to-head clinical trial; and CH-4051, which is in the Phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, it develops antifolate program, a second platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of immune-mediated inflammatory disorders, including transplant rejection, autoimmune diseases, psoriasis, and systemic lupus erythematosus.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is an international specialty pharmaceutical company. The Company’s product portfolio consists of four categories of products: India branded generics, US generics, international branded generics and active pharmaceutical ingredients (API). The products of the Company are prescribed in therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. The products manufactured by the Company include Supatret, Winolap, Donamem, Exmasin, Lenzest, Octride Depot 10, Carcidox, Tyrogef, Cernos depot, Milnorm, Levipil, Exzilor and Macorate. The Company’s subsidiaries include Sun Pharma Global Inc. BVI., Sun Pharma Global-FZE, Sun Pharmaceutical (Bangladesh) Ltd., Sun Pharmaceutical Peru S.A.C. and Sun Farmaceutica Ltda-Brazil. In November 2008, the Company, along with its subsidiaries, completed the acquisition of Chattem Chemicals, Inc.

"Osme" means smell in Greek, and Osmetech is intent on finding ways to sniff out what's wrong with people. Founded in 1993, the company has several molecular diagnostics products on the market. Its eSensor system can detect RNA and DNA targets, such as genes that indicate sensitivity to certain drugs, as well as for detecting cystic fibrosis carriers. Though headquartered in the UK, the company's principal operations are in the US. Its diagnostic systems, tubes, and microarrays are used by hospitals, laboratories, and physician practices through its US sales force and a network of international distributors.

Roche Diagnostics Corporation company was founded in 1998 and is headquartered in Indianapolis, Indiana. Roche Diagnostics Corporation operates as a subsidiary of Roche Holding AG. Roche Diagnostics Corporation offers diagnostic tests and systems. The company operates in the diagnostic areas of diabetes care, centralized diagnostics, applied science, molecular diagnostics, and point-of-care diagnostics. Its products include diagnostics tools that test for congestive heart failure, HIV, Hepatitis B and C, fertility, and diabetes diseases. The company supplies its products to researchers, physicians, patients, hospitals, and laboratories. It has facilities in Indiana, New Jersey, South Carolina, Colorado, New Hampshire, Puerto Rico, and California, as well as locations in Canada.

Capellon was founded in 1999. Capellon Pharmaceuticals is helping curb the common cold. Capellon Pharmaceuticals company's product portfolio includes Liquibid, Rescon, and Tussi-bid, prescription remedies for cough and congestion. Other products target various allergies as well as respiratory, gastrointestinal, and bladder ailments. Capellon concentrates its efforts on marketing products it already has and acquiring products useful to it current customer base. With an intense focus on growth it looks for partners with whom it can co-promote new drugs whenever possible.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.